NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.16, Zacks reports. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.28 million.
NRx Pharmaceuticals Trading Up 14.0%
NRXP opened at $2.45 on Wednesday. The company has a 50 day moving average of $2.77 and a 200 day moving average of $2.97. The company has a market cap of $106.94 million, a PE ratio of -7.21 and a beta of 2.11. NRx Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $5.05.
Analyst Ratings Changes
A number of research analysts have recently weighed in on NRXP shares. BTIG Research increased their target price on shares of NRx Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, November 11th. Wall Street Zen downgraded NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. HC Wainwright reissued a “buy” rating on shares of NRx Pharmaceuticals in a report on Tuesday, August 25th. Wolfe Research assumed coverage on NRx Pharmaceuticals in a report on Thursday, October 15th. They set an “outperform” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Tuesday, November 3rd. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $35.00.
Read Our Latest Stock Report on NRXP
More NRx Pharmaceuticals News
Investors following NRXP have been watching these news items:
- Positive Sentiment: The FDA approved NRx’s preservative-free ketamine in October, and the company has begun selling it with a 17-person sales team. NRx says it has received its first order and expects shipments to start by January 2027; it estimates the U.S. market at about $400 million, with potential to expand through additional sterile products. NRx third-quarter results and corporate update
- Positive Sentiment: NRx reported a third-quarter loss of $0.05 per share, narrower than analyst estimates, while net loss fell to $2.2 million from $5.9 million a year earlier. The company also reported $19.8 million in cash and no convertible debt. Zacks quarterly results
- Positive Sentiment: Zacks Research upgraded NRXP from “strong sell” to “hold,” a modest improvement in its rating outlook.
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company’s candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.
Featured Stories
- Five stocks we like better than NRx Pharmaceuticals
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
